All articles by Miranda Mclaren

Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?

Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a…
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026

Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing…
Year in review: EmVenio in 2025

From a rebrand to clinical trial facilitation to the conference circuit, EmVenio covered a lot of ground. Here are some…
Potency assays in cell therapies: A look behind the challenges

Dr. Scott Jones has spent more than 35 years advancing assay development and currently leads BioBridge Global’s R&D department. His…
Clinical trial predictions and the role of technology in 2026

Looking ahead to 2026, the clinical research landscape is entering a pivotal phase. As trial design innovations, hybrid studies, and…

Meet the new EmVenio in 2026

Clinical research is evolving, but access to trials remains uneven. Many patients still face barriers to participation, and sponsors are…
Why researchers are bringing cardiovascular trials to the heart of the community

Cardiovascular disease (CVD), a broad term for conditions affecting the heart and blood vessels, remains the leading cause of death…
Meet the new EmVenio at OCT events across 2026

Looking towards 2026, clinical trial teams continue to face challenges surrounding recruitment and retention, while many patients continue to confront…
Why the industry needs to rethink its approach to IRT for smarter trials

With the role of automating patient randomisation and supply management, IRT is a critical backbone for trial execution, yet it…
Reducing white space in early development: Four regulatory pitfalls to avoid pre-IND

In a clinical development world divided by phases, transitions are critical at every step. The transition from nonclinical testing to…

Sections